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Abstract
Interferon (IFN)-b inhibits cell proliferation and affects cell cycle in keratinocytes transformed by both mucosal high risk
Human Papilloma Virus (HPV) and cutaneous HPV E6 and E7 proteins. In particular, upon longer IFN-b treatments, cutaneous
HPV38 expressing cells undergo senescence. IFN-b appears to induce senescence by upregulating the expression of the
tumor suppressor PML, a well known IFN-induced gene. Indeed, experiments in gene silencing via specific siRNAs have
shown that PML is essential in the execution of the senescence programme and that both p53 and p21 pathways are
involved. IFN-b treatment leads to a modulation of p53 phosphorylation and acetylation status and a reduction in the
expression of the p53 dominant negative DNp73. These effects allow the recovery of p53 transactivating activity of target
genes involved in the control of cell proliferation. Taken together, these studies suggest that signaling through the IFN
pathway might play an important role in cellular senescence. This additional understanding of IFN antitumor action and
mechanisms influencing tumor responsiveness or resistance appears useful in aiding further promising development of
biomolecular strategies in the IFN therapy of cancer.
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Introduction
The group of cellular proteins known as Interferons (IFNs)
appeared to be expressed in infected cells as an early response to
viral infection but, in addition to their antiviral activity, IFNs also
have a profound effect on cell growth [1].
IFN-a2 was the first human protein shown to be effective for
cancer treatment and the first economically viable clinical product
developed from recombinant DNA technology in cancer therapy.
Antitumor activity of IFNs is probably exerted through direct
and indirect mechanisms. It is conceivable that numerous direct
effects play a central role in the overall antitumor response, such as
down-regulation of oncogene expression, induction of differenti-
ation, inhibition of cell cycle progression and induction of tumor
suppressor genes, and programmed cell death [2]. However,
additional understanding of IFN antitumor action and mecha-
nisms influencing tumor responsiveness or resistance appears
necessary to aid further promising development of biomolecular
strategies in IFN therapy of cancer.
The most extensively studied anticancer treatment-induced
mechanism is apoptotic programmed cell death. Nevertheless, the
correlation between the induction of apoptosis and drug response
cannot explain the overall tumor cell sensitivity [3]. Numerous
recent studies have shown that in cells where apoptosis is blocked,
non-apoptotic cell death or irreversible cell growth arrest, namely
senescence, can be activated as potential tumor-suppressor
mechanisms [4]. The concept of senescence is applied in general
to the irreversible proliferative arrest of cells caused by various
stresses [5] including oxidative damage, telomere dysfunction, and
DNA damage. One particularly relevant source of stress in tumor
cells is derived from the aberrant proliferative signals of oncogenes
which may trigger senescence through a process known as
oncogene-induced senescence, functioning as a potential tumor
suppressor mechanism.
Senescent cells are identified in vitro by distinctive morphological
changes, such as large cell size, flat vacuolated morphology, the
inability to synthesize DNA, the formation of domains of
heterochromatin called Senescence-Associated Heterochromatin
Foci (SAHF) and the expression of a Senescence-Associated b-
galactosidase activity (SA-b-gal) [6,7]. One of the earliest steps in
the senescence programme is the translocation of histone
chaperone HIRA (Histone Repression factor A) into promyelo-
cytic leukemia (PML) nuclear bodies (NBs), but the role played by
HIRA localization into PML bodies has not yet been identified.
PML bodies are nuclear structures known to serve as sites of
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regulatory complexes, and have been extensively implicated in
the induction of senescence and apoptosis [8,9].
Consistent with its role in tumor suppression, the critical
senescence pathways converge on the two major tumor suppressor
genes p53 and pRb, whose mutations or inactivation are most
common in all cancers [10].
Abrogation of senescence can be achieved by SV40 large T, a
combination of HPV oncoproteins E6 and E7, E1A and MDM2
coexpression or small interfering RNA against pRb and p53 [11].
Tumors initiated by loss of p53 can be eliminated by senescence
induced by p53 restoration, tumor regression being achieved
through an innate immune response that leads to the clearance of
senescent cells [12,13]. Cellular senescence results in altered gene
expression including IFNs and their related genes [14]. PML is
known to be regulated by the interferon pathway via the STAT
transcription factors [15]. IFN also regulates many other
components of PML nuclear bodies, suggesting that in conjunction
they mediate the antiviral and antiproliferative activities of this
cytokine [9]. Cellular senescence is induced in human fibroblasts
by prolonged IFN-b treatment through DNA damage signaling
and a p53-dependent pathway [16]. IFN-a also induces replicative
senescence in endothelial cells after continuous stimulation [17].
Taken together, these studies suggest that signaling through the
IFN pathway might play an important role in cellular senescence.
Human Papilloma Viruses (HPVs) are small DNA viruses
involved in the development of both benign and malignant lesions
localised in different anatomic districts, that are able to replicate
exclusively in the stratified squamous cutaneous and mucosal
epithelium. More than 100 different HPV types have been isolated
so far, and they can be sub-grouped into cutaneous or mucosal
according to their ability to infect the skin or the mucosa of the
genital or upper-respiratory tracts [18]. To date, the causative
association between mucosal high risk-HPV and cervical carcino-
ma has been clearly demonstrated. It is well known that the
expression of E6 and E7 viral oncoproteins is a common feature of
cervical cancer cells and is strongly implicated in the process of
cancer development, E6 and E7 principally targeting and
inhibiting p53 and pRb tumor suppressor proteins, respectively
[19]. Emerging lines of evidence support the involvement of the
cutaneous HPV types belonging to the beta genus in non
melanoma skin cancer (NMSC). However, although the role of
beta HPV types in NMSC in Epidermodysplasia verruciformis
(EV) patients is well accepted, their involvement in skin
carcinogenesis in the general population is not entirely proven.
The transforming properties of the majority of cutaneous HPV
types have been poorly investigated. Tommasino and co-workers
[20] have shown that HPV38 E7 appears to act similarly to
HPV16 E7, by binding to pRB and promoting its degradation via
the proteasome pathway. On the contrary, HPV38 E6 oncopro-
tein differs from mucosal high risk HPV E6 proteins in the
mechanism by which it counteracts p53 activity. The expression of
HPV38 E6 and E7 in human keratinocytes induces the
stabilization of p53, which in turn selectively activates transcrip-
tion of DNp73, a p53 inhibitor [21]. High DNp73 levels have been
found in a number of human malignancies including cancers of
the breast, prostate, liver, lung and thyroid [22]. Recently, it has
been shown that IFN-a reduces DNp73 levels in Huh7 hepatoma
cells, and this effect correlates to increased susceptibility to IFN-a
triggered apoptosis [23].
Here, we show that prolonged treatment with IFN-b induces
senescence in cutaneous HPV38-transformed keratinocytes. PML
is essential in IFN-b induction of senescence in HPV38-
transformed keratinocytes, and both p53 and p21 pathways
contribute to the execution of the phenomenon. p53 colocalyzes
with IFN-b-induced PML into PML Nuclear Bodies. By
recruitment of p53 into NBs, IFN-b can modulate p53 post-
translational modification at specific phosphorylation and acety-
lation sites and downregulate DNp73 expression, leading to the
recovery of p53 transactivating activity of selected target genes
involved in cell proliferation control.
Results
IFN-b Inhibits Cell Proliferation of K38 and K16 Cells
Keratinocytes expressing E6 and E7 proteins of HPV-38 and
HPV-16, referred to as K38 and K16 respectively, were obtained
as described [20].
To test whether IFN-b could affect proliferation of both
transformed keratinocytes, K-38 and K-16 cells were treated with
IFN-b for several time points and the amounts of viable cells were
revealed. As shown in Fig. 1A, proliferation of both cell lines was
strongly affected by IFN-b.
To exclude that the antiproliferative effect of IFN-b could be
due to downregulation of E6/E7 expression, we checked HPV-38
and HPV-16 E6 and E7 mRNA levels by RT-PCR. No significant
variations were observed in either E6 or E7 expression in K38 and
K16 cells upon treatment with IFN-b for different time points
(data not shown).
We previously demonstrated that IFN-b exerts its antiprolifer-
ative effect on high-risk HPV-positive cell lines by lengthening cell
cycle S-phase progression [24]. We analyzed cell cycle distribution
of K38 and K16 cells after treatment with IFN-b for several time
points. Both cell lines showed a significant augment of S-phase cell
amount starting from 48 h of treatment. Interestingly, in K16 cells
S-phase cell accumulation increased with time whereas in K-38
cells the S-phase increase was followed by an augment of G1
population (Fig.1B).
K16 and K38 cells were pulse-labelled with BrdU for 5 h and
analysed for BrdU incorporation. As with what was observed in
SiHa and other mucosal high-risk HPV-positive cell lines [24], an
increased number of BrdU-positive cells reflecting an S-phase cell
accumulation was revealed in IFN-b treated K16 populations. On
the contrary, in K-38 samples the number of cells incorporating
BrdU upon IFN-b treatment appeared clearly reduced (Fig. 1C).
IFN-b Induces Cellular Senescence in K38 but Not in K16
Cells
To study apoptosis and senescence induction, specific assays
were performed. Annexin-V externalization assay showed no
significant increase of apoptosis in either cell types after IFN-b
treatment (data not shown). Senescent cells were quantified by
counting cells displaying b-galactosidase activity at pH 6.0 (SA-
bgal). This lysosomal hydrolase is elevated in senescent cells as a
result of lysosomal activity at suboptimal pH, which is detectable
only in senescent cells due to an increase in lysosomal content.
Interestingly, increasingly high percentages of senescent cells were
observed exclusively in K38 cells transformed by E6 and E7
proteins of cutaneous HPV genotype, starting from 4 days of IFN-
b treatment, compared to control keratinocytes (LXSN), K16 cells
and mucosal high risk HPV-positive cell lines (Fig. 2A, B, and C).
Involvement of PML, p53 and p21 in Cell Senescence
Induced by IFN-b in K-38 Cells
It is known that important senescence regulators are found in
IFN-inducible genes. In addition, it has been reported that
prolonged IFN-b stimulation can induce senescence in normal
cells through the activation of a DNA damage response triggered
IFNb-Induced Senescence and p53 Activity
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could induce the senescence phenotype in K38 cells through the
involvement of PML and the activation of p53, thus counteracting
the inhibitory action exerted on p53 by HPV-38 E6/E7
expression. We analysed the protein levels of PML, p53 and
p21, upon IFN-b treatment, and the respective involvement in
senescence through RNA silencing (siRNA) technique. Three
different siRNAs were used for PML, p53 and p21 genes. Upon
IFN-b treatment, PML was up-regulated as well as p21 (Fig. 3).
On the other hand in K16 cells, even if IFN-b treatment induces
PML expression, it is not detectable any increase in p21 protein
levels (data not shown).
PML seems to be an essential component of senescence
response in K38 cells, since, when PML expression is inhibited
by specific siRNAs (Fig. 4A), IFN-b-induced senescence is strongly
reduced (Fig. 4D). p21 silencing (Fig. 4C) partially affects IFN-b-
induced senescence (Fig. 4D), while p53 silencing (Fig. 4B) appears
much more effective (Fig. 4D), suggesting that different p53 targets
may be involved in IFN-b-induced senescence in K38 cells and
different pathways may cooperate towards this phenomenon.
PML Target Proteins Colocalyze in PML Nuclear Bodies
It is known that PML recruits into NBs p53 and different
proteins involved in p53 post-translational modifications that are
critical for the activation of p53 and for the selection of target
genes [25]. We studied colocalization of PML with p53 and
DNp73 through confocal microscopy analyses of K38 cells treated
with IFN-b for different time points. Fig. 5 shows that p53 (A) and
DNp73 (B) colocalyze with IFN-b-induced PML into PML NBs.
On the other hand, colocalization is not detectable after PML
silencing (data not shown).
Post-translational Modification of p53 by IFN-b
The expression of HPV38 E6 and E7 in human keratinocytes
induces the stabilization of p53, as shown by WB analysis of p53 in
K38 cells compared with control keratinocytes (LXSN), K16 cells
and high risk HPV-positive cell lines SiHA and ME-180 (Fig. 6A).
This p53 stabilization can be related to increased phosphorylation
[21] and acetylation (Fig. 6C).
In this respect, we may hypothesize that IFN-b, through PML
up-regulation, can lead to the recovery of p53 transactivating
activity of target genes involved in cell proliferation control.
Therefore p53 phosphorylation and acetylation status was
analyzed in K38 cells treated with IFN-b. IFN-b modulates p53
phosphorylation status at different phosphorylation sites (Ser-6,
Ser-15, Ser-46, Ser-392, Fig. 6B) while acetylation is mainly
downregulated in Lys-320 (Fig. 6C). Ser-6, Ser-392, and Lys-320
seem to be the most important p53 post-translational modifica-
tions involved in IFN-b-induced senescence in K38 cells. In fact,
when PML expression is silenced, IFN-b is not able to modulate
p53 Ser-6, Ser-392, and Lys-320 status (Fig. 6D).
Accardi et al. [21] reported that p53 stabilization in K38 cells
leads to transcriptional activation of DNp73, a p53 inhibitor, able
to inhibit p53 transactivation of genes involved in cell growth
suppression. It has been shown that IFN-a reduces DNp73 levels
in Huh7 hepatoma cells and this effect correlates to increased
susceptibility to IFN-a triggered apoptosis [23]. We observed that
in K38 cells, IFN-b treatment downregulates DNp73 mRNA levels
(data not shown). The DNp73 protein expression appears to be
reduced upon IFN-b treatment (Fig. 6E), probably as a result of
the p53 post-translational modifications induced by IFN-b. In fact,
when PML expression is silenced, DNp73 protein levels are not
downregulated by IFN-b (Fig. 6D).
Real time PCR array results indicate that some genes involved
in senescence and growth control are IFN-b-upregulated (Fig.6F).
In particular, the observed induction of p53 target genes Bax and
Pig3 indicates that IFN-b treatment leads to the recovery of p53
transactivating activity of selected target genes involved in the
control of cell proliferation. In fact, it has been reported that
modification of specific p53 phosphorylation and acetylation sites
may correlate to the transactivation of growth related genes,
suggesting a tissue and promoter-specific p53 activity regulation
[26]. PML depletion reduces IFN-b induction of Bax and Pig3 in
K-38 cells (Fig.6F), indicating the role of PML in the ability of
IFN-b to recover p53 transactivation activity of specific target
genes.
Discussion
IFNs were the first successful biological therapy for human
malignancy and currently there are several approved IFN cancer
therapies. Clinical effectiveness of different IFN subtypes in
treatment of various forms of cancer has been extensively reviewed
[1]. Better definition of therapeutic molecular targets appears to be
critical to fully realize the potential of IFNs in oncology and
further understand the mechanisms of antitumor action of the IFN
family.
Senescence is a permanent cell cycle arrest that is resistant to
growth factors and other signals that induce cell proliferation. It
has been proposed that senescence prevents cancer in the early
stages of its development [6]. Tumor suppressors such as p53, pRb
and PML are critical regulators of senescent programme [10,25],
and genes required for senescence are often found to be mutated
in human cancers. Cellular senescence is induced in human
fibroblasts by prolonged IFN-b treatment through DNA damage
signaling and a p53-dependent pathway [16]. IFN-a also induces
replicative senescence in endothelial cells after continuous
stimulation [17], and treatment with IFN-c induces cellular
senescence in young human umbilical vascular endothelial cells
[27]. However, whether induction of senescence is sufficient to
repress tumor in vivo is controversial. Recent reports showed that
conditional restoration of p53 in mice with hepatocarcinomas,
sarcoma or lymphoma is able to promote tumor regression
[13,12]. In addition, it has been reported that HeLa cells cease
proliferation and undergo senescence by introduction of the
bovine papillomavirus E2 gene that inhibits the expression of the
Figure 1. IFN-b affects cell proliferation in K16 and K38 cells. (A) IFN-b inhibits cell proliferation in K16 and K38 cells. Cells were seeded in
triplicate at 10
5 cells per 35 mm dish and, after 24 h, IFN-b was added to the cultures for the indicated times. IFN-b treated and control cells were
counted in a hemocytometer and viability was evaluated by trypan blue exclusion. Data represent means 6 s.d. of three independent experiments.
**=p,0.01; ***=p,0.001. (B) IFN-b treatment differently affects cell cycle progression of K16 and K38 cells. K16 and K38 cells were treated with IFN-
b for the indicated time points. DNA staining was performed by incubating cells in PBS containing 0.18 mg/ml propidium iodide and 0.4 mg/ml
DNase-free RNase. Cells were analysed on a FACScan flow cytometer. DNA profiles, derived from one representative experiment of three performed,
are shown. (C) IFN-b treatment differently affects DNA synthesis in K16 and K38 cells. To determine the number of S-phase nuclei, cells were plated in
triplicate at 10
5 cells per 35 mm dish, treated with IFN-b for different time points and incubated with 50 mM BrdU for the last 5 hours. BrdU treated
samples were then fixed and stained with an anti-BrdU monoclonal antibody followed by a rhodamine conjugated goat anti-mouse antibody. BrdU-
positive cells were counted under a fluorescence microscope. Data represent means 6 s.d. of three independent experiments.
doi:10.1371/journal.pone.0036909.g001
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HPV16 E6 and E7 genes transfected in SiHa cells contributed
to apoptosis and senescence [29].
In contrast to mucosal high-risk HPV types, the involvement of
cutaneous HPV types in human carcinogenesis is still unclear.
Cutaneous HPV types that belong to the beta genus of the HPV
phylogenetic tree were first isolated in patients suffering from EV,
a rare autosomal recessive cancer-prone genetic disorder, and are
consistently detected in NMSC from EV, immunocompromised
and normal individuals [30]. The transforming properties of the
majority of the cutaneous HPV types have been poorly
investigated. It has been reported that cutaneous HPV5 E6
protein targets and abrogates Bak function by promoting its
proteolitic degradation both in vitro and in regenerated epithelium
[31]; however, regulation of Bax has also been reported [32]. The
E6 protein of HPV5 compromises the repair of UV-induced
thymine dimers [33] and E6 of HPV7 forces keratinocytes into the
S1-phase by inhibiting p53-activated, pro-apoptotic genes [34].
HPV8 E6 is able to bind XCRR1 that functions in a single strand
DNA repair [35] and it has been shown that UV-irradiated
cutaneous HPV8 E2-transgenic mice develop invasive carcinoma-
tous lesions more rapidly than non-irradiated counterparts [36].
Moreover, E6/E7 expression of HPV20 influences proliferation
and differentiation of the skin of UV-irradiated transgenic mice
[37]. The anti-apoptotic activity and the delay of the DNA repair
mechanism may lead to the persistence of UV-damaged kerati-
nocytes, suggesting that cutaneous HPV types may be involved in
the early stages of carcinogenesis.
A different mechanism behind the lack of cell cycle arrest in
cutaneous HPV expressing cells is the up-regulation of DNp73 as a
result of p53 accumulation observed in HPV38 E6 and E7
expressing human keratinocytes. DNp73 in turn inhibits the
capacity of p53 to induce the transcription of genes involved in
growth suppression [20,21]. This observation, together with the
efficiency of pRb binding and degradation by HPV38 E7, the
HPV38 E6/E7-induced suboptimal activation of telomerase and
the HPV38 E6/E7 transforming properties in vivo [38], seems to
indicate that HPV38 E6 and E7, differently from proteins of other
cutaneous HPV types, may be involved in the maintenance of
oncogenic transformation.
We have previously reported that type I IFNs inhibit cell
proliferation in high risk mucosal HPV-positive Squamous
Carcinoma Cell (SCC) lines by inducing a significant accumula-
tion of cells in S-phase [24]. The S-phase deregulation triggers
apoptotic cell death specifically mediated by the pro-apoptotic
factor TRAIL [39].
The present study shows that IFN-b affects cell proliferation in
keratinocytes expressing E6 and E7 proteins of cutaneous HPV-38
to a greater extent than in E6 and E7 mucosal HPV-16
transformed cells. In particular, K38 cells undergo senescence
upon prolonged IFN-b treatment. IFN-b appears to induce
senescence by up-regulating the expression of the tumor suppres-
sor PML. Indeed, experiments of gene silencing via specific
siRNAs have shown that PML is essential in the execution of
senescence programme and that both p53 and p21 pathways are
involved in senescence induction by IFN-b in K38 keratinocytes.
P53 and PML are critical mediators of senescence. PML is
essential for the formation of discrete protein assemblages in the
nucleus known as Nuclear Bodies (NBs) [40]. PML recruits into
NBs p53 and proteins involved in p53 post-translational modifi-
cations that are essential for the activation of p53 and for the
selection of target genes, such as the DNA damage responsive
kinases ATM and ATR [25]. ATM kinase phosphorylates p53 at
Ser-15, a senescence-inducible modification [41], in IFN-b-
induced cellular senescence in human fibroblasts [16]. Over-
expression of PML is capable of inducing premature senescence by
stabilizing p53 via p53 acetylation on Lys-382 and phosphoryla-
tion on Ser-15 and Ser-46 [42]. In contrast, deacetylation of p53
antagonizes PML-induced premature senescence [43].
It has been shown that PML interacts with CBP/p300
acetyltransferase and stabilizes p53 through Lys-382 acetylation
[42]. PML also recruits the tumor suppressor homeodomain-
interacting protein kinase-2 (HIPK2) which induces p53Ser46
phosphorylation [44]. It has been reported that HIPK2-mediated
phosphorylation of p53Ser46 is required for the CBP-induced p53
acetylation at Lys-382 [45]. PML has also been recently identified
as a direct target of p53 revealing a regulatory positive feedback
loop between p53 and PML [46].
Our results indicate that in K38 cells p53 colocalyzes with IFN-
b-induced PML into PML NBs. IFN-b can significantly modulate
Figure 2. IFN-b induces senescence in K38 cells. (A) Control keratinocytes (LXSN), K16, K38 cells and high risk HPV-positive squamous carcinoma
cell lines ME-180, Caski, HeLa and SiHa were treated with IFN-b for 4 days and senescent cells were quantified by counting cells displaying senescent-
associated b-galactosidase (SA-bgal) activity at pH 6.0. (B) Percentage of senescent cells in K16 and K38 cells treated with IFN-b for different time
points. (C) SA-bgal-positive K38 blue cells observed under a light microscope after 4 days of IFN-b treatment. *=p,0.05; ***=p,0.001.
doi:10.1371/journal.pone.0036909.g002
Figure 3. IFN-b affects the expression of proteins involved in senescence in K38 cells. Western blot analysis of PML, p53 and p21
expression in K38 treated with IFN-b for different time points. Whole cell extracts were resolved on SDS-PAGE and transferred onto PVDF membrane.
Immunoblotting was performed as reported in M&M.
doi:10.1371/journal.pone.0036909.g003
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status mainly at Lys-320. It has been also shown that p53
acetylation in Lys-320 is the first step in IFN-b-induced senescence
in human fibroblasts [16].
DNA damage response is required for the activation of p53 in
response to oncogenes. Oncogene induced senescence is accom-
pained by DNA replicative stress, including prematurely termi-
nated DNA replication forks and DNA double-strand breaks
caused by hyper-DNA replication [47]. Consistent with this, Ras-
induced senescence is associated with activation of DNA damage
response effectors, such as ATM/ATR and Chk2/Chk1, and
inactivation of these DNA damage effectors by RNA interference
attenuates oncogene induced senescence [48,49]. We observed
that the inhibition of ATM and ATR prevents IFN-b induction of
senescence in K38 keratinocytes, suggesting that IFN-b might
induce senescence through a p53-dependent DNA damage
pathway (data not shown).
It has been reported that HPV16 E6 mediates resistance to IFN-
induced senescence through inhibition of p53 acetylation by
binding to CBP/p300. Conversely, treatment of HPV16 E7-
expressing cells with IFN ultimately resulted in cellular senescence
through a process that is dependent upon acetylation of p53 by
CBP/P300 [50]. Moreover, HPV16 E7 up-regulates SIRT1, thus
attenuating p53 activity via its deacetylation [51]. It has been
shown that HPV16 E6 can induce multiple site phosphorylation of
p53 [52]. HPV38 E6 and E7 expression in human keratinocytes
induces phosphorylation of p53, which leads to the up-regulation
of DNp73 and the inhibition of p53 transcriptional induction of
genes involved in growth suppression [21]. All together these
observations indicate that p53 post-translational modifications are
critical for p53 involvement in senescence programme induced by
IFN-b and that modulation of p53 activity could be a common
strategy utilized by both mucosal and cutaneous HPV to inhibit
p53 function.
Figure 4. Effect of PML, p53 and p21 silencing on senescence induction by IFN-b in K38 cells. PML (A), p53 (B) and p21 (C) were silenced
by specific small interfering RNAs and protein expression was analyzed by Western blot in cells treated with IFN-b for 4 days. (D) Senescence
induction by IFN-b (4 days treatment) was evaluated by SA-bgal staining. *=p,0.05; **=p,0.01.
doi:10.1371/journal.pone.0036909.g004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36909Figure 5. p53 and DNp73 co-localyze with IFN-b-induced PML into PML Nuclear Bodies. (A,B) For confocal microscopy analysis, K38 cells
were cultured on glass bottom dishes (MatTek Corporation) and treated with IFN-b for 4 days. Cells were then fixed in PBS 4% paraformaldehyde for
30 min on ice, immuno-fluorescence labelling was performed as described in Materials and Methods and sample were analyzed using confocal
microscope (Leica TCS SP5).
doi:10.1371/journal.pone.0036909.g005
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36909We report that by recruitment of p53 into NBs via PML
induction, IFN-b may modulate p53 phosphorylation and
acetylation status and downregulate DNp73 expression in K38
keratinocytes, leading to the recovery of p53 transactivating
activity of selected target genes involved in cell proliferation
control. Real time PCR array confirms that some genes involved
in senescence and growth control are IFN-b-upregulated, in
agreement with the reported observations [25] that modification of
specific p53 phosphorylation and acetylation sites may correlate to
the transactivation of growth related genes, suggesting a tissue and
promoter-specific p53 activity regulation.
Our results contribute to one of the most interesting current
research questions about the exact contribution of post-transla-
tional modification sites to the selectivity of the global transcrip-
tional programme of p53. Other important questions remain to be
answered to clarify the multitude and redundancy of p53 covalent
post-translational modifications required for p53-dependent se-
nescence. It is possible that no single specific post-translational
modification leads to specific p53 gene transactivation activity, but
each modification might help to regulate p53 function in a tissue
and promoter-specific manner.
Materials and Methods
Cell Cultures and Treatments
Primary human foreskin keratinocytes were transduced with
empty retrovirus pLXSN (control), or with pLXSN38E6E7 or
pLXSN16E6E7 as described by Caldeira et al., 2003 [20] and
were grown in KBM BulletKit (Lonza).
HPV16-positive cell line Caski and SiHa, HPV18-positive cell
line HeLa, and HPV68-positive cell line ME180, obtained from
the American Type culture Collection, were grown in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine serum.
Cells were maintained in a humidified atmosphere of 5.5% CO2
at 37uC.
Human recombinant IFN-b (Rebif; 3610
8 IU/mg of protein;
Ares-Serono) was added to the medium at the concentration of
200 IU/ml.
Measurement of Cell Proliferation
Transformed keratinocytes were seeded in triplicate at 10
5 cells
per 35 mm dish. After 24 h, IFN-b was added to the cultures for
the indicated times. Adherent cells were detached with 0.05%
trypsin-0.02% EDTA in PBS, suspended in growth medium, and
counted in a hemocytometer. Viability was evaluated by trypan
blue exclusion.
Flow Cytometry
For cell cycle analysis, cells were fixed in 70% ice-cold ethanol
for at least 30 min. DNA staining was performed by incubating
cells in PBS containing 0.18 mg/ml propidium iodide and
0.4 mg/ml DNase-free RNase. Cells were analysed on a FACScan
flow cytometer (Becton and Dickinson).
BrdU Incorporation
To determine the number of S-phase nuclei, cells were plated in
triplicate at 10
5 cells per 35 mm dish, treated with IFN-b for
different time points and incubated with 50 mM BrdU for the last
5 hours. Samples were fixed with 95% ethanol, 5% acetic acid,
treated with 1.5 M HCl and stained with an anti-BrdU
monoclonal antibody (Amersham) followed by a rhodamine
conjugated goat anti-mouse antibody (Cappel).
Senescence-associated b-galactosidase Staining
Cells were plated in 12 multi-well, 0,5610
5 cells per well, and
treated with IFN-b at different time points. Senescent cells were
quantified by counting cells displaying senescent-associated b-
galactosidase activity at pH 6.0, assayed through Senescent
Detection Kit (Calbiochem) following manufacturer’s instruction.
Western Blot Analysis
To analyse protein expression, control and IFN-b treated cells
were lysed in SDS reducing sample buffer. Total cell extracts were
clarified by centrifugation and boiled in the presence of 5% 2-
Mercaptoethanol and 0.01% bromophenol blue. Protein concen-
tration was determined (Bio-Rad Protein Assay) and 30 mg of total
proteins were resolved on SDS-PAGE and transferred onto PVDF
membrane (Amersham). The membranes were blocked with 5%
skim milk dissolved in PBS-T and incubated with primary
antibodies (mouse anti-p53; rabbit anti-p21 (Santa Cruz); rabbit
anti-PML (Bethyl); rabbit anti-phospho-p53 Ser6, anti-phospho-
p53 Ser15, anti-phospho-p53 Ser46, anti-phospho-p53 Ser392
(Cell Signaling); rabbit anti-acetyl-p53 Lys320, anti-acetyl-p53
Lys373/382 (Millipore), and anti-human b tubulin mouse IgG1
antibody (ICN), as an internal control. Immune complexes were
detected with horseradish peroxidase-conjugated goat anti-rabbit
and anti-mouse antiserums (ICN) followed by enhanced chemilu-
minescence reaction (Millipore).
PML, p53 and p21 silencing
Small interfering RNAs (siRNAs) targeted to PML, p53 and p21
were designed and validated by Qiagen and a non-silencing
siRNA (Qiagen) served as control.
PML siRNAs were: 1) Sense:59-CGUCUUUUUCGAGAGU-
CUGtt-39;Antisense:59-CAGACUCUCGAAAAAGACGtt-39;
2)Sense:59-CCCGCAAGACCAACAACAUtt-39; Antisense: 59-
AUGUUGUUGGUCUUGCGGGtg-39; 3)Sense:59-GGGACC-
CUAUUGACGUUGAtt-39; Antisense: 59-UCAACGU-
CAAUAGGGUCCCtg-39.
p53 siRNA were: 1) Sense:59–GGAAAUUUGCGUGUGGA-
GUtt-39; Antisense: 59–CUCCACACGCAAAUUUCCtt-39;2 )
Sense: 59-GCAUCUUAUCCGAGUGGAAtt-39; Antisense: 59-
UUCCACUCGGAUAAGAUGCtg-39; 3) Sense: 59-GCA-
GUUAAGGGUUAGUUUAtt-39; Antisense: 59-UAAA-
CUAACCCUUAACUGCaa-39.
p21 siRNA (Dharmacon) was: Sense:5’-GAUGGAACUUC-
GACUUUGUUU-3’: Antisense:5’-PACAAAGUCGAAGUUC-
CAUCUU 3’.
Figure 6. IFN-b effect on p53 post-translational modification and expression of its target genes. (A) WB analysis of p53 in control
keratinocytes (LXSN), K16 and K38 cells and in high risk HPV-positive squamous carcinoma cell lines SiHa and ME-180 treated with IFN-b for 48 h. (B)
WB analysis of p53 phosphorylated at different phosphorylation sites. (C) WB analysis of acetylated p53. (D) WB analysis of phosphorylated and
acetylated p53 and DNp73 in K38 cells silenced by PML siRNA and treated with IFN-b for 48 h. (E) WB analysis of DNp73 in K38 cells treated with IFN-b
for different time points. Whole cell extracts were resolved on SDS-PAGE and transferred onto PVDF membrane. Immunoblotting was performed as
reported in M&M. (F) Real time PCR analysis of Bax and Pig3 was carried out on K38 cells treated with IFN-b for 48 h, also in the presence of PML
siRNA. NT = not transfected. *=p,0.05; **=p,0.01.
doi:10.1371/journal.pone.0036909.g006
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5 cells per dish were seeded in
35 mm dishes in 1 ml of fully supplemented culture medium.
siRNA was diluted in 50 ml culture medium without supplements
to a final concentration of 10 nM. 3.5 ml of HiPerfect Transfection
Reagent (Qiagen) were added to the diluted siRNA and mixed by
vortexing. After an incubation of 10 min at room temperature, the
transfection complex was added drop-wise onto the cells. 24 hrs
post-transfection cells were treated with IFN-b for the indicated
time points.
Immunofluorescence
Immunofluorescence staining of cells was performed on cells
grown on Glass Bottom Culture Dishes 14 mm Microwell poly-d-
lysine Coated from Mat Tek Corporation (Ashland, MA 01721
U.S.A.) and fixed with 4% formaldehyde, permeabilized with
PBS/0.1% Triton-X, and stained using the following primary
antibodies: anti-PML; ap53 (Santa Cruz), anti-DNp73 (Imgenex).
Anti-mouse-Fitc (Cappel), anti-mouse-Alexa 546 (Molecular Probe
# A11030), and anti-rabbit-Alexa 610 (Molecular Probe #
A31551) were used as secondary antibodies. Sample were
analyzed using confocal microscope (Leica TCS SP5). Software:
LAS AF version 1.6.3 (Leica Microsystem).
Real-time PCR
Real-time PCR was carried out by using the MESA GREEN
MasterMixes Plus, Low ROX (Eurogentec). The primer sequences
are: Bax F: 5’ TTT GCT TCA GGG TTT CAT CC 3’, R: 5’
ATC CTC TGC AGC TCC ATG TT 3’; Pig3 F: 5’ GCT TCA
AAT GGC AGA AAA GC 3’, R: 5’ AAC CCA TCG ACC ATC
AAG AG 3’.
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